New program with payors aims to accelerate patient access to medical devices

FDA Commissioner Scott Gottlieb says that "advancing the public health means helping to make sure patients have access to safe, effective medical products." On Wednesday, the agency announced new steps to expand its work with private payors.

FDA Commissioner Scott Gottlieb says that "advancing the public health means helping to make sure patients have access to safe, effective medical products." On Wednesday, the agency announced new steps to expand its work with private payors. The Private Payor Program is a voluntary opportunity for manufacturers to receive feedback from the FDA and other non-governmental health technology assessors/payors on what’s needed in order to develop a more efficient evidence generation strategy during the FDA pre-submission meeting. CareFirst BlueCross BlueShield and United Health Group have joined FDA's growing list of private payors available to participate in medical device manufacturer pre-submission meetings. By facilitating communications between device makers and payors, FDA hopes to shorten the time between FDA approval and coverage decisions. This can be particularly beneficial for manufacturers creating new and innovative devices who also need to secure coverage of their devices by payors.